https://www.benzinga.com/general/biotech/25/01/42883730/solid-biosciences-outpaces-competitors-in-duchenne-gene-therapy-development
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED) - Solid...
Jan 8, 2025 - Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones.
gene therapy developmentsolidbiosciencesoutpacescompetitors
https://www.techtarget.com/pharmalifesciences/news/366607770/FDA-Aims-to-Bolster-Gene-Therapy-Development-with-New-Guidance
FDA Aims to Bolster Gene Therapy Development with New Guidance | TechTarget
With more than 900 INDs for gene therapies currently in development, a new deluge of FDA final and draft guidances aim to accelerate gene therapy development....
gene therapy developmentnew guidancefdaaimsbolster